How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy
A Biederstädt, K Rezvani - Blood, 2023 - ashpublications.org
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potentially curative
treatment for patients with high-risk acute leukemias, but unfortunately disease recurrence …
treatment for patients with high-risk acute leukemias, but unfortunately disease recurrence …
Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia
MH Hodroj, I Abou Dalle, N Moukalled… - Frontiers in …, 2023 - frontiersin.org
The outcome of B-cell acute lymphoblastic leukemia (B-ALL) has improved over time with
the incorporation of multi-agent chemotherapy in the treatment landscape as well as the …
the incorporation of multi-agent chemotherapy in the treatment landscape as well as the …
Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the …
Donor lymphocyte infusion has been used in the management of relapsed hematologic
malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal …
malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal …
Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European …
Although second allogeneic haematopoietic cell transplantation (allo‐HCT 2) is a
therapeutic option for patients relapsing after first HCT (allo‐HCT 1), there is limited data on …
therapeutic option for patients relapsing after first HCT (allo‐HCT 1), there is limited data on …
Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions
I Varadarajan, E Pierce, L Scheuing… - OncoTargets and …, 2023 - Taylor & Francis
Allogeneic hematopoietic cell transplantation (allo-HCT) represents an important and
potentially curative treatment option for adult patients with acute lymphoblastic leukemia …
potentially curative treatment option for adult patients with acute lymphoblastic leukemia …
The BLIND study: blinatumomab and DLI approach for management of B-ALL relapse after allogeneic stem cell transplantation. A multicentric Italian experience
S Giammarco, R Maggi, L Di Marino… - Bone Marrow …, 2024 - nature.com
Allogeneic hematopoietic stem cell transplantation (alloHSCT) offers a potentially curative
option for acute lymphoblastic leukemia (ALL). The 5-year overall survival is only 30–40% in …
option for acute lymphoblastic leukemia (ALL). The 5-year overall survival is only 30–40% in …
Comparison of outcomes of donor lymphocyte infusions with or without lenalidomide in patients with hematological malignancies post allogeneic HSCT
S Punatar, V Murugaiyan, K Kumbhalwar… - Indian Journal of …, 2023 - Springer
Outcomes with DLI alone for post-transplant relapsed hematological malignancies are poor
especially in acute leukemias. Addition of immunomodulatory drugs to DLI may augment …
especially in acute leukemias. Addition of immunomodulatory drugs to DLI may augment …
Combination therapy with chemotherapy, donor lymphocyte infusion with concurrent Blinatumomab in relapsed/refractory acute precursor B-lymphoblastic leukemia
HJ Choi, JY Choi, BK Kim, HY An… - Journal of Pediatric …, 2021 - journals.lww.com
The therapeutic approach for relapsed/refractory acute lymphoblastic leukemia (ALL)
remains to be a challenge. The patient was diagnosed as B-cell ALL at 6 months of age and …
remains to be a challenge. The patient was diagnosed as B-cell ALL at 6 months of age and …
[PDF][PDF] Combined adoptive immunotherapy with Blinatumomab and donor lymphocyte infusions in children with relapsed/refractory B-ALL after allogeneic stem cells …
LA Tsvetkova, OV Paina, PV Kozhokar - Cell Ther Transplant, 2022 - cttjournal.com
Allo-HSCT is potential curative option for high-risk pediatric B-cell acute leukemia (B-ALL),
nevertheless about 30-70% of patients relapsed after allo-HSCT. Patients with …
nevertheless about 30-70% of patients relapsed after allo-HSCT. Patients with …